These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 35646096)
1. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer. He J; Hu X; Chen L; Liu Q; Jiang Y Front Genet; 2022; 13():850290. PubMed ID: 35646096 [No Abstract] [Full Text] [Related]
2. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052 [TBL] [Abstract][Full Text] [Related]
3. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets. Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582 [TBL] [Abstract][Full Text] [Related]
4. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501 [TBL] [Abstract][Full Text] [Related]
5. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer. Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285 [TBL] [Abstract][Full Text] [Related]
6. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532 [TBL] [Abstract][Full Text] [Related]
7. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing. Yu Y; Qian J; Shen L; Ji W; Lu S Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109 [TBL] [Abstract][Full Text] [Related]
8. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC. Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807 [TBL] [Abstract][Full Text] [Related]
9. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761 [TBL] [Abstract][Full Text] [Related]
11. Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma. Song Z; Cai Z; Yan J; Shao YW; Zhang Y Transl Lung Cancer Res; 2019 Aug; 8(4):392-400. PubMed ID: 31555514 [TBL] [Abstract][Full Text] [Related]
12. Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples. Werner TV; Kock S; Weber I; Kayser G; Werner M; Lassmann S J Mol Diagn; 2022 Jul; 24(7):784-802. PubMed ID: 35787794 [TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers. Wu H; Ji H; Yang W; Zhang M; Guo Y; Li B; Wang J; Chen R; Chen Y; Wang X BMC Cancer; 2022 Sep; 22(1):1020. PubMed ID: 36167530 [TBL] [Abstract][Full Text] [Related]
14. Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens. Liu L; Shao D; Deng Q; Tang H; Wang J; Liu J; Guo F; Lin Y; Peng Z; Mao M; Kristiansen K; Ye M; He J J Thorac Dis; 2018 May; 10(5):2631-2637. PubMed ID: 29997924 [TBL] [Abstract][Full Text] [Related]
15. A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer. Jin S; Zhou C; Hou X; Fan Z; Zhao J; Ai X; Chu Y; Chen R; Guo R; Chen L Transl Lung Cancer Res; 2020 Aug; 9(4):1507-1515. PubMed ID: 32953522 [TBL] [Abstract][Full Text] [Related]
16. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374 [TBL] [Abstract][Full Text] [Related]
17. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111 [TBL] [Abstract][Full Text] [Related]
18. Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA. Li J; Chen S; Xue H; Wang H; Huang T; Xie H; He J; Ke C; Yu Z; Ni B Onco Targets Ther; 2022; 15():571-584. PubMed ID: 35615557 [TBL] [Abstract][Full Text] [Related]
19. Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer. Choudhury Y; Tan MH; Shi JL; Tee A; Ngeow KC; Poh J; Goh RR; Mong J Front Med (Lausanne); 2022; 9():758464. PubMed ID: 35223889 [TBL] [Abstract][Full Text] [Related]
20. Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study. Chang SC; Wei YF; Chen CY; Lai YC; Hu PW; Hung JC; Chang CY Mol Diagn Ther; 2024 Nov; 28(6):803-810. PubMed ID: 39147938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]